Enterprise Value
154.1M
Cash
177.6M
Avg Qtr Burn
-68.18M
Short % of Float
6.56%
Insider Ownership
0.87%
Institutional Own.
61.63%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roxadustat (ROW) Details Chronic kidney disease, Anemia | Approved Quarterly sales | |
Roxadustat Details Chemotherapy Induced Anemia | PDUFA Approval decision | |
Phase 3 Data readout | ||
Pamrevlumab Details Duchenne muscular dystrophy | Phase 3 Update | |
Roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
Phase 2/3 Data readout | ||
FG-3246+ enzalutamide Details Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
FG-3246 (ADC) Details Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
FG-3165 Details Cancer, Solid tumor/s | Phase 1 Initiation | |
Pamrevlumab Details COVID-19, Infectious disease | Failed Discontinued | |
Roxadustat (U.S.) Details Anemia, Chronic kidney disease | Failed Discontinued | |
Pamrevlumab Details Idiopathic pulmonary fibrosis | Failed Discontinued |